GEISTWERT Rechtsanwälte Lawyers Avvocati

UPC-CFI-0001086/2026

Abbott Diabetes Care Inc. v. Shenzhen SiSensing Co., Ltd, SiBionics GmbH, Sibio Technology Limited, Sibio PTE Ltd., Shanghai International Holding Corp. GmbH

Datum
2026-09-07
Kammer
Milan (IT) Local Division
Verfahrensart
Provisional measures
Sprache
EN

Metadaten

Fall-IDUPC-CFI-0001086-2026-bb7ad749c876
AktenzeichenUPC-CFI-0001086/2026
RegisterzeichenUPC-CFI-0001086/2026
Entscheidungsreferenz
Schlagwörter
Leitsätze

Dokumente und Volltext

Textextraktion: pypdf | Seiten: 44

COURT OF FIRST INSTANCE MILAN LOCAL DIVISION UPC CFI no. 1086/2026 order issued on 7 September 2026 HEADNOTES: The Court considers that, in the specific circumstances of the present case, the new defence arguments submitted by the respondents for the first time in their last written submission concerning the interpretation and infringement of feature 1.6 are admissible. For the purpose of assessing the admissibility of the new arguments raised by the respondents with regard to the interpretation and infringement of feature 1.6, the following considerations are relevant. First, it should be emphasised that claim construction is a matter of law, on which the Court may therefore also elaborate ex officio. The classification of this issue as a matter of law also entails that, had this Court he ...